Reinhard von Roemeling
Direttore Tecnico/Scientifico/R&S presso CURIS, INC.
Posizioni attive di Reinhard von Roemeling
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| CURIS, INC. | Direttore Tecnico/Scientifico/R&S | 13/08/2019 | - |
Storia della carriera di Reinhard von Roemeling
Precedenti posizioni note di Reinhard von Roemeling
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
HUYA Bioscience International LLC
 HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Direttore Tecnico/Scientifico/R&S | - | - |
Formazione di Reinhard von Roemeling
| Johann Wolfgang Goethe-Universität Frankfurt am Main | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 3 |
| Germania | 2 |
Posizioni
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| CURIS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
HUYA Bioscience International LLC
HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Health Technology |